Interesting what happened with share price back in May 2019 when they announced "First Patients Complete Nerve Regeneration Trial", share price jumped from 11 cents on 29/04/2019 to 42 cents on 6/05/2019. Australian Super became a substantial holder on 14/05/2019 with a share price of around 49 cents at that time. What are people thoughts on repeating this massive share price jump (4.5x times)? Will a partnership with J&J (if it happens) be the catalyst for such a massive re-rate? Is there anything else that might attract institutional investors to invest in OCC?
OCC Trading, page-1000
-
- There are more pages in this discussion • 801 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
66.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $139.0M | |||
| Open | High | Low | Value | Volume |
| 66.5¢ | 66.5¢ | 64.5¢ | $276.6K | 421.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 25500 | 65.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 66.0¢ | 9999 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| OCC (ASX) Chart |